EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study

OBJECTIVES: Historically, resection followed by chemotherapy was standard treatment for stage II-III non-small cell lung cancer (NSCLC) and selected patients with stage IB disease. However, recurrence was common post-resection. Genomic characterization of early-stage NSCLC and precision medicine have since provided more effective therapies. Real-world evidence prior to practice-changing approvals aids understanding of the disease and treatment landscape, and establishment of benchmarks for future studies. We report an international, retrospective, real-world study of patients with early-stage NSCLC. MATERIALS AND METHODS: Medical records were reviewed for patients

• Lin, S. H.
• Kahangire, D. A.
• Nagar, S. P.
• Ahn, M. J.
• Affi, R.
• Agulnik, J.
• Shih, J. Y.
• Hochmair, M. J.
• Tufman, A.
• Debieuvre, D.
• Chow, J.
• Jimenez, M.
• Davis, K. L.
• Sandelin, M.
• Veluswamy, R. R.